Roxane Fights Vanda Antipsychotic Dose Patent In Fed. Circ.

Law360, Washington (December 5, 2017, 9:59 PM EST) -- Roxane Laboratories told a Federal Circuit panel Tuesday that Vanda Pharmaceuticals' dosage method patent for its antipsychotic Fanapt is “quintessential conventional activity,” in its effort to overturn a Delaware court's finding its proposed generic version of the drug infringed the patent.

In the oral arguments, Roxane fought a district court finding that a post-invention 400-fold increase in the value of Fanapt indicated the nonobviousness of the patent. Roxane said using the little-used dosage-adjustment patent, which halves dosage for patients with a certain genetic feature, can’t block...
To view the full article, register now.